APG Asset Management N.V. Has $119.68 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

APG Asset Management N.V. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 21.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,869,560 shares of the biopharmaceutical company’s stock after selling 517,467 shares during the quarter. APG Asset Management N.V.’s holdings in Gilead Sciences were worth $119,683,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Gilbert & Cook Inc. lifted its holdings in shares of Gilead Sciences by 5.3% in the fourth quarter. Gilbert & Cook Inc. now owns 6,791 shares of the biopharmaceutical company’s stock valued at $550,000 after purchasing an additional 344 shares in the last quarter. Aveo Capital Partners LLC boosted its holdings in Gilead Sciences by 8.6% during the 4th quarter. Aveo Capital Partners LLC now owns 5,473 shares of the biopharmaceutical company’s stock worth $443,000 after acquiring an additional 435 shares during the last quarter. Steward Partners Investment Advisory LLC grew its stake in shares of Gilead Sciences by 2.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 32,155 shares of the biopharmaceutical company’s stock worth $2,605,000 after acquiring an additional 651 shares in the last quarter. TD Asset Management Inc raised its holdings in shares of Gilead Sciences by 33.1% in the fourth quarter. TD Asset Management Inc now owns 1,029,657 shares of the biopharmaceutical company’s stock valued at $83,413,000 after purchasing an additional 256,039 shares during the last quarter. Finally, Legacy Advisors LLC bought a new position in shares of Gilead Sciences during the fourth quarter valued at about $216,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $70.00 price objective on shares of Gilead Sciences in a research report on Monday, September 16th. Raymond James raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target for the company in a research report on Monday, July 8th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Robert W. Baird restated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Thursday, June 20th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Twelve analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $82.06.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the sale, the insider now directly owns 114,979 shares in the company, valued at approximately $8,506,146.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the transaction, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,847 shares of company stock valued at $3,002,940. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 1.0 %

Shares of GILD stock opened at $83.04 on Friday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86. The company’s fifty day simple moving average is $77.64 and its two-hundred day simple moving average is $71.45. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The stock has a market capitalization of $103.46 billion, a price-to-earnings ratio of 230.67, a PEG ratio of 2.91 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The company had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. As a group, analysts anticipate that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a $0.77 dividend. The ex-dividend date of this dividend is Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.71%. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.